Back to Search
Start Over
Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma
- Source :
- Internal Medicine
- Publication Year :
- 2019
- Publisher :
- The Japanese Society of Internal Medicine, 2019.
-
Abstract
- Although multiple myeloma (MM) had been an incurable hematological malignancy with a poor prognosis, recent advances in novel anti-neoplastic agents, including carfilzomib (a proteasome inhibitor), have improved the prognosis. We herein report two cases of congestive heart failure in patients treated with carfilzomib. Although there are some reports on the cardiotoxicity of carfilzomib, to our knowledge, this is the first report on the cardiac involvement of carfilzomib in Japanese MM patients. We review the critical points from our two cases, with the aim of avoiding carfilzomib-associated heart failure in MM patients.
- Subjects :
- Oncology
Male
medicine.medical_specialty
Poor prognosis
Case Report
Antineoplastic Agents
030204 cardiovascular system & hematology
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Recurrence
Internal medicine
Internal Medicine
medicine
Humans
In patient
Multiple myeloma
Heart Failure
Cardiotoxicity
carfilzomib
cardiotoxity
business.industry
General Medicine
Middle Aged
medicine.disease
Prognosis
Carfilzomib
multiple myeloma
chemistry
Hematological malignancy
Heart failure
Proteasome inhibitor
030211 gastroenterology & hepatology
Female
business
Oligopeptides
Proteasome Inhibitors
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 13497235 and 09182918
- Volume :
- 58
- Issue :
- 11
- Database :
- OpenAIRE
- Journal :
- Internal Medicine
- Accession number :
- edsair.doi.dedup.....9039c86b6983974536722eac843d6c6c